The UK medicines regulator has finalized much-awaited guidance explaining how drug sponsors can conduct randomized controlled trials (RCT) primarily using real-world data (RWD) sources to support a regulatory decision relating to a medicinal product.
Its use could make it more feasible for sponsors to repurpose their existing medicines for new conditions and help bring life-changing new medicines more quickly to those who need them,